{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:39:04Z","timestamp":1792791544475,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T00:00:00Z","timestamp":1502150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"GTF"},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pearl Therapeutics"},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Forest"},{"name":"Meda"},{"name":"Verona"},{"name":"Theravance"},{"name":"Mylan"},{"name":"Innoviva"},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.rmed.2017.07.011","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T18:30:48Z","timestamp":1500489048000},"page":"238-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Efficacy and safety of glycopyrrolate\/eFlow\u00ae CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials"],"prefix":"10.1016","volume":"132","author":[{"given":"Edward","family":"Kerwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Goodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tosiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary T.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rmed.2017.07.011_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/resp.12660","article-title":"Global burden of COPD","volume":"21","author":"Lopez-Campos","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.rmed.2017.07.011_bib2","series-title":"Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)","author":"Global Strategy for the Diagnosis","year":"2017"},{"issue":"4","key":"10.1016\/j.rmed.2017.07.011_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/thorax.55.4.289","article-title":"A\u00a0randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group","volume":"55","author":"van Noord","year":"2000","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.rmed.2017.07.011_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2017.07.011_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3132\/pcrj.2008.00024","article-title":"Comparison of tiotropium bromide and combined ipratropium\/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study","volume":"17","author":"Griffin","year":"2008","journal-title":"Prim. Care Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2017.07.011_bib6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.rmed.2017.07.011_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.rmed.2004.02.013","article-title":"Resource use and risk factors in high-cost exacerbations of COPD","volume":"98","author":"Oostenbrink","year":"2004","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.07.011_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1465-9921-14-112","article-title":"COPD symptoms in the morning: impact, evaluation and management","volume":"14","author":"Roche","year":"2013","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2017.07.011_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1378\/chest.127.1.335","article-title":"Device selection and outcomes of aerosol therapy: evidence-based guidelines: American college of chest physicians\/American college of asthma, allergy, and immunology","volume":"127","author":"Dolovich","year":"2005","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2017.07.011_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4212\/cjhp.v65i2.1118","article-title":"Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease","volume":"65","author":"Batterink","year":"2012","journal-title":"Can. J. Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.rmed.2017.07.011_bib11","first-page":"324","article-title":"Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers","volume":"53","author":"Khassawneh","year":"2008","journal-title":"Respir. Care"},{"issue":"1","key":"10.1016\/j.rmed.2017.07.011_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000109374","article-title":"Dry powder inhalers: which factors determine the frequency of handling errors?","volume":"75","author":"Wieshammer","year":"2008","journal-title":"Respiration"},{"issue":"3","key":"10.1016\/j.rmed.2017.07.011_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/089426803769017613","article-title":"Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care","volume":"16","author":"Molimard","year":"2003","journal-title":"J.\u00a0Aerosol Med."},{"issue":"10","key":"10.1016\/j.rmed.2017.07.011_bib14","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.arcped.2007.06.017","article-title":"Assessment of the handling of inhaler devices: an observational study of children in primary care","volume":"14","author":"Malot","year":"2007","journal-title":"Arch. Pediatr."},{"issue":"3","key":"10.1016\/j.rmed.2017.07.011_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/COPD.S3036","article-title":"Medication adherence issues in patients treated for COPD","volume":"3","author":"Restrepo","year":"2008","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"issue":"6","key":"10.1016\/j.rmed.2017.07.011_bib16","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00166410","article-title":"What the pulmonary specialist should know about the new inhalation therapies","volume":"37","author":"Laube","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.07.011_bib17","first-page":"23","article-title":"Considerations for managing chronic obstructive pulmonary disease in the elderly","volume":"9","author":"Taffet","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.rmed.2017.07.011_bib18","first-page":"7","article-title":"Guiding principles for the use of nebulized long-acting beta2-agonists in patients with COPD: an expert panel consensus","volume":"4","author":"Wise","year":"2017","journal-title":"Chron. Obstruct Pulmon Dis. (Miami)"},{"key":"10.1016\/j.rmed.2017.07.011_bib19","first-page":"131","article-title":"Inhalation drug delivery devices: technology update","volume":"8","author":"Ibrahim","year":"2015","journal-title":"Med. Devices (Auckl)"},{"issue":"1","key":"10.1016\/j.rmed.2017.07.011_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/15412555.2011.630047","article-title":"The role of nebulized therapy in the management of COPD: evidence and recommendations","volume":"9","author":"Dhand","year":"2012","journal-title":"COPD"},{"issue":"2","key":"10.1016\/j.rmed.2017.07.011_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/jamp.2013.1038","article-title":"Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate","volume":"27","author":"Mahler","year":"2014","journal-title":"J.\u00a0Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.rmed.2017.07.011_bib22","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2147\/COPD.S114034","article-title":"A\u00a0review of nebulized drug delivery in COPD","volume":"11","author":"Tashkin","year":"2016","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"10.1016\/j.rmed.2017.07.011_bib23","first-page":"A5472","article-title":"In-vitro characterization of the eFlow\u00ae Closed System (eFlow\u00ae CS) nebulizer with glycopyrrolate inhalation solution (SUN-101)","volume":"195","author":"Pham","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2017.07.011_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/15412555.2012.761960","article-title":"Inhaler devices for patients with COPD","volume":"10","author":"Fink","year":"2013","journal-title":"COPD"},{"issue":"9770","key":"10.1016\/j.rmed.2017.07.011_bib25","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0140-6736(10)60926-9","article-title":"Aerosol drug delivery: developments in device design and clinical use","volume":"377","author":"Dolovich","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rmed.2017.07.011_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/rmed.2001.1292","article-title":"Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease","volume":"96","author":"Barta","year":"2002","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2017.07.011_bib27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1513\/pats.200701-016FM","article-title":"Pharmacologic interventions chronic obstructive pulmonary disease: bronchodilators","volume":"4","author":"Hanania","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"2","key":"10.1016\/j.rmed.2017.07.011_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/ageing\/afl174","article-title":"Inhaled therapy in elderly COPD patients; time for re-evaluation?","volume":"36","author":"Jarvis","year":"2007","journal-title":"Age Ageing"},{"key":"10.1016\/j.rmed.2017.07.011_bib29","series-title":"Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)","author":"Global Strategy for the Diagnosis","year":"2014"},{"key":"10.1016\/j.rmed.2017.07.011_bib30","series-title":"Clinical Trials with Missing Data: a Guide for Practitioners","author":"O'Kelly","year":"2014"},{"issue":"11","key":"10.1016\/j.rmed.2017.07.011_bib31","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/thorax.56.11.880","article-title":"Health status measurement in chronic obstructive pulmonary disease","volume":"56","author":"Jones","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2017.07.011_bib32","article-title":"Results of a pulmonologist survey regarding attitudes and practices with inhalation devices for COPD","volume":"193","author":"Braman","year":"2016","journal-title":"Am. J. Resp. Crit. Care"},{"issue":"2","key":"10.1016\/j.rmed.2017.07.011_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/jam.2006.19.127","article-title":"Prescription bias and factors associated with improper use of inhalers","volume":"19","author":"Sestini","year":"2006","journal-title":"J.\u00a0Aerosol Med."},{"issue":"2","key":"10.1016\/j.rmed.2017.07.011_bib34","first-page":"174","article-title":"Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric","volume":"49","author":"Rau","year":"2004","journal-title":"Resp. Care"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461111730210X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461111730210X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:42:16Z","timestamp":1760614936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461111730210X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":34,"alternative-id":["S095461111730210X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.07.011","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of glycopyrrolate\/eFlow\u00ae CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}